New York City, NY, United States
New York City, NY, United States

The Icahn School of Medicine at Mount Sinai , formerly the Mount Sinai School of Medicine , is an American medical school in the New York City borough of Manhattan in the state of New York. Chartered by Mount Sinai Hospital in 1963, the ISMMS is one of the foremost medical schools in the United States, ranking 19th in research according to U.S. News & World Report, 18th in NIH funding among U.S Medical Schools , and 3rd in NIH funding per primary investigator.ISMMS and the Mount Sinai Hospital occupy a four-block area adjacent to Central Park on the Upper East Side of Manhattan, with architecture designed by I. M. Pei. ISMMS and Mount Sinai Hospital comprise the Mount Sinai Medical Center, of which Kenneth L. Davis, MD, is the president and CEO.In 2012–13, The Mount Sinai Medical Center was recognized on the U.S. News & World Report "Best Hospitals Honor Roll," ranking 14th among the approximately 5000 hospitals in the US with 11 nationally ranked specialties including cancer, geriatrics, gastroenterology, cardiology & heart surgery, otolaryngology, rehabilitation, diabetes & endocrinology, neurology & neurosurgery, gynecology, urology, and kidney disorders. Wikipedia.


Time filter

Source Type

Patent
Servicio Andaluz De Salud and Mount Sinai School of Medicine | Date: 2017-05-10

The present invention describes the use of a group of single-nucleotide polymorphisms (SNPs) or variants in the gene NFKB1 in order to obtain data useful for the prognosis of a disease occurring with sensorineural hearing loss, and to the kit or devices and uses thereof.


Patent
Mount Sinai School of Medicine | Date: 2017-04-05

A bioreactor system for preparing a cardiac organoid chamber and for subsequent testing thereof is described herein and shown in the exemplary drawing figures. The bioreactor system includes a first vessel having a hollow interior and an open top. A first cover is mated with the open top of the first vessel. The first cover has a first opening formed therein. The system further includes a cannula having a lumen that extends from an open first end to an open second end. The cannula is disposed within the first opening of the first cover such that a portion of the cannula lies below the first cover and for insertion into the hollow interior of the first vessel. A porous ring is coupled to the cannula at or proximate the open second end thereof. The system also includes a balloon catheter having an inflatable balloon at a distal end of a catheter shaft. The balloon catheter is adapted to pass through the lumen of the cannula when the balloon is in a deflated state. The balloon catheter is axially adjustable within the lumen to allow the balloon in an inflated state to be disposed adjacent: (1) the open second end of the cannula; and (2) the porous ring for preparing the cardiac organoid chamber about the inflated balloon and porous ring. The cannula and porous ring construction and combination allows for the balloon to be deflated and removed from the lumen of the cannula while the engineered cardiac organoid chamber remains attached to the porous ring. This permits the testing of organoid pump function, such as organoid pressure and volume characteristics, without having to transfer the engineered cardiac organoid from one tool (e.g., an incubation tool) to another tool (e.g., a functional testing apparatus).


Patent
Mount Sinai School of Medicine | Date: 2017-01-18

Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine and dibenzoazepine compounds and similar genera:


Patent
Genisphere Inc and Mount Sinai School of Medicine | Date: 2017-02-08

Provided are peptide biomarkers for diagnosis of allergy, monitoring development of clinical tolerance in an allergic individual, and predicting whether an allergic subject is likely to develop clinical or natural tolerance over time. The invention also relates to diagnostic methods and diagnostic kits employing the peptide biomarkers.


Patent
King's College London and Mount Sinai School of Medicine | Date: 2016-12-28

Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.


The present disclosure relates to methods for the treatment of sarcoidosis. In certain aspects and embodiments, the disclosure provides compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof and/or the use of such compositions for the treatment of Sarcoidosis. In another aspect, the disclosure relates to compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof plus a second active agent. In yet another aspect, the disclosure relates to kits containing agents useful for the treatment of sarcoidosis.


Patent
Mount Sinai School of Medicine | Date: 2017-06-14

A stable pharmaceutical composition formulated for parenteral administration to a human and comprising a purified recombinant human wild-type -galactosidase A and 1-deoxygalactonojirimycin in a pharmaceutically acceptable carrier.


Patent
Mount Sinai School of Medicine and Yale University | Date: 2017-01-27

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).


Patent
Mount Sinai School of Medicine and Western Sydney Local Health District | Date: 2017-01-18

A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstutial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.


Lunnon K.,Mount Sinai School of Medicine
Nature neuroscience | Year: 2014

Alzheimer's disease (AD) is a chronic neurodegenerative disorder that is characterized by progressive neuropathology and cognitive decline. We performed a cross-tissue analysis of methylomic variation in AD using samples from four independent human post-mortem brain cohorts. We identified a differentially methylated region in the ankyrin 1 (ANK1) gene that was associated with neuropathology in the entorhinal cortex, a primary site of AD manifestation. This region was confirmed as being substantially hypermethylated in two other cortical regions (superior temporal gyrus and prefrontal cortex), but not in the cerebellum, a region largely protected from neurodegeneration in AD, or whole blood obtained pre-mortem from the same individuals. Neuropathology-associated ANK1 hypermethylation was subsequently confirmed in cortical samples from three independent brain cohorts. This study represents, to the best of our knowledge, the first epigenome-wide association study of AD employing a sequential replication design across multiple tissues and highlights the power of this approach for identifying methylomic variation associated with complex disease.

Loading Mount Sinai School of Medicine collaborators
Loading Mount Sinai School of Medicine collaborators